Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data

 
• By Sue Sutter
  
Baseball backstop
Amylyx's withdrawal pledge provided a nonbinding backstop to FDA's decision to approve Relyvrio on the basis of a single study. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from Product Reviews